{"gene":"ARRB2","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2020,"finding":"Dopamine receptor DRD5, via EFD and IYX(X)I/L motifs in its C-terminal and IC3 loop, directly recruits both TRAF6 and ARRB2 to form a multi-protein complex also containing TAK1, IKKs, and PP2A. Within this complex, ARRB2 acts as a negative regulator of TRAF6, and the DA-DRD5-ARRB2-PP2A signaling axis impairs TRAF6-mediated activation of NF-κB and expression of pro-inflammatory genes.","method":"Co-immunoprecipitation, domain-mapping mutagenesis (EFD and IYX(X)I/L motif mutations), in vivo mouse models (S. aureus sepsis and meningitis), macrophage knockdown/overexpression experiments","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with domain-mapping mutagenesis, multiple orthogonal cellular and in vivo functional assays in a single focused study","pmids":["32035036"],"is_preprint":false},{"year":2015,"finding":"ARRB2 directly participates in an AKT/ARRB2/PDE4 trimeric complex that is recruited into the lipid raft to degrade cAMP. miR-150 represses ARRB2 (and PDE4) expression and prevents this complex from entering the lipid raft, thereby interrupting cAMP degradation and inhibiting IL-2 and TNF production via the NF-κB pathway.","method":"miRNA overexpression with western blot, RT-PCR; lipid raft fractionation; co-immunoprecipitation of AKT/ARRB2/PDE4 complex; luciferase reporter assay for miR-150 targeting of ARRB2","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple orthogonal methods (Co-IP, fractionation, reporter assay) in a single lab; complex membership established but reconstitution not performed","pmids":["26549736"],"is_preprint":false},{"year":2023,"finding":"Loss of BMPR2 in pulmonary artery smooth muscle cells (PASMC) causes upregulation of ARRB2 via a pERK1/2-pP38-pSMAD2/3 cascade. Elevated ARRB2 in turn activates pAKT-mediated inactivation of GSK3-beta, drives CTNNB1 (β-catenin) nuclear translocation, and reduces RHOA and RAC1, producing a hypocontractile, hyperproliferative phenotype. Genetic reduction of ARRB2 in BMPR2-deficient PASMC restores normal signaling and contractility and prevents persistent pulmonary hypertension in mice with inducible SMC-specific BMPR2 loss.","method":"SMC-specific Bmpr2 knockout mice, siRNA knockdown in human PASMC, PASMC from PAH patients with BMPR2 mutation, western blot for pERK1/2, pP38, pSMAD2/3, ARRB2, pAKT, GSK3β, β-catenin, RHOA, RAC1; echocardiography, RVSP measurement, proliferation/contractility assays","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (BMPR2 KO + ARRB2 reduction rescue) with multiple orthogonal cellular and in vivo phenotypic readouts across mouse and human PASMC models","pmids":["36744494"],"is_preprint":false},{"year":2012,"finding":"β-arrestin 2 (ARRB2/β-arr2) sequesters JNK in the cytoplasm of dorsal root ganglion neurons; deletion of β-arr2 results in altered intracellular distribution of JNK and phospho-cJun, and unmasks morphine-specific (but not fentanyl-specific) activation of the JNK cascade. JNK inhibitors reverse the enhanced analgesia, reduced locomotion, and enhanced sensitization phenotypes of β-arr2-/- mice to wild-type levels, placing ARRB2 as a negative regulator of JNK signaling downstream of mu-opioid receptor activation.","method":"β-arr2 knockout mice, pharmacological JNK inhibitors (two compounds), immunofluorescence for phospho-cJun nuclear localization in DRG neurons, behavioral assays (analgesia, locomotion, sensitization), PKC inhibitor comparison","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with pharmacological epistasis using two independent JNK inhibitors and multiple behavioral readouts; ligand-specificity controls (morphine vs. fentanyl) strengthen mechanism","pmids":["22491351"],"is_preprint":false},{"year":1994,"finding":"The human ARRB2 gene was chromosomally mapped to band 17p13 by fluorescence in situ hybridization (FISH), establishing its physical genomic location.","method":"Fluorescence in situ hybridization (FISH) on human chromosomes","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cytogenetic mapping by FISH, single lab, single method","pmids":["7695743"],"is_preprint":false},{"year":2021,"finding":"In endothelial progenitor cells (EPCs), ARRB2 physically interacts with and activates ERK1/2 and AKT signaling pathways, promoting EPC proliferation, migration, adhesion, tube formation, and protection from hypoxia-induced apoptosis. ARRB2-overexpressing EPCs transplanted into ischemic hind-limb mice showed significantly improved blood flow restoration and capillary density.","method":"Lentivirus-mediated overexpression and knockdown of Arrb2 in EPCs, Co-IP for ARRB2-ERK1/2 and ARRB2-AKT interaction, proliferation/migration/tube formation assays, Arrb2-deficient mice with hind-limb ischemia model, laser Doppler measurements, histology","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP plus multiple functional assays plus in vivo rescue, single lab","pmids":["32863967"],"is_preprint":false},{"year":2021,"finding":"ARRB2 induces hepatic lipid metabolism disorders and lipid accumulation through the AMPK pathway in alcoholic fatty liver, increasing both fatty acid and cholesterol synthesis; knockdown of Arrb2 in mouse liver in vivo and in AML-12 cells in vitro reversed lipid accumulation, and LC-MS metabolomics identified primary bile acids as the most significantly altered hepatic lipid metabolites.","method":"In vivo Arrb2 knockdown in AFL mice, siRNA and pEX3-Arrb2 overexpression in AML-12 cells, western blot for AMPK pathway proteins, LC-MS metabolomics","journal":"Clinical science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro loss/gain-of-function with AMPK pathway readout plus metabolomics; single lab","pmids":["33871024"],"is_preprint":false},{"year":2021,"finding":"ARRB2 promotes colorectal cancer cell growth, motility, and apoptosis resistance by regulating the expression of Wilms tumor 1 associated protein (WTAP); knockdown of ARRB2 decreased WTAP expression and attenuated cancer pathway activation.","method":"ARRB2 knockdown in CRC cell lines, western blot, AOM/DSS mouse model, cell proliferation/migration/apoptosis assays","journal":"Acta biochimica et biophysica Sinica","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single KD approach; mechanism linking ARRB2 to WTAP not biochemically defined at the protein-protein level","pmids":["33367479"],"is_preprint":false},{"year":2021,"finding":"GPR54 (KISS1R) requires ARRB2 as a functional adaptor to mediate neuroprotective effects of kisspeptin-54 (KP54); ARRB2 siRNA knockout offsets the neuroprotective effects of KP54, and the pathway operates through ARRB2/AKT/GSK3β to reduce oxidative stress and neuronal apoptosis after subarachnoid hemorrhage.","method":"ARRB2 siRNA intracerebroventricular administration in rats, GPR54 antagonist (KP234), western blot, immunofluorescence, behavioral tests, TUNEL/Fluoro-Jade C staining in SAH rat model","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (siRNA) and pharmacological epistasis in a well-defined in vivo model with multiple orthogonal phenotypic readouts; single lab","pmids":["33989759"],"is_preprint":false},{"year":2025,"finding":"SUMOylated TRPC1 in microglia facilitates interaction between TRPC1 and ARRB2; normally ARRB2 binds to NLRP3 to suppress inflammasome activation. SUMOylation of TRPC1 disrupts the NLRP3/ARRB2 complex by competing for ARRB2 binding (ARRB2 binds residues 46–61 of TRPC1 N-terminus), thereby activating NLRP3 signaling and exacerbating neuroinflammation after stroke.","method":"Co-IP for TRPC1-ARRB2 and NLRP3-ARRB2 interaction, TRPC1 SUMOylation-deficient mice, MCAO/R model, oxygen-glucose deprivation/regeneration in vitro, domain mapping (TRPC1 residues 46–61), western blot, behavior and infarct volume measurements","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping and genetic loss-of-function model; single lab but multiple orthogonal methods","pmids":["39921112"],"is_preprint":false},{"year":2023,"finding":"WDR4 acts as an adaptor that promotes nuclear localization of DDX20 and bridges DDX20 with transcription factor Egr1, thereby inhibiting Egr1-promoted transcriptional expression of ARRB2. This WDR4-mediated transcriptional suppression of ARRB2 contributes to bladder cancer progression and lymph node metastasis.","method":"Co-IP for WDR4-DDX20-Egr1 complex, subcellular fractionation for DDX20 nuclear localization, luciferase reporter for Egr1-driven ARRB2 transcription, WDR4 knockdown/overexpression in bladder cancer cells, in vivo metastasis models, IHC","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP plus transcriptional reporter plus in vivo functional data; single lab","pmids":["37783676"],"is_preprint":false},{"year":2024,"finding":"STAT5B acts as a transcription factor that directly drives ARRB2 transcription downstream of PRL/PRLR signaling; ARRB2 in turn physically binds ERK1/2, enhancing phosphorylation of ERK1/2 and activating the MAPK pathway to promote prostate cancer progression.","method":"ChIP-qPCR and luciferase reporter gene assay for STAT5B binding to ARRB2 promoter; Co-IP for ARRB2-ERK1/2 interaction; STAT5B and ARRB2 knockdown in VCaP and 22Rv1 cells; in vitro and in vivo tumor assays; IHC for pSTAT5B, ARRB2, pERK1/2","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, luciferase reporter, and Co-IP in single lab with in vivo validation; multiple orthogonal methods","pmids":["38341429"],"is_preprint":false},{"year":2022,"finding":"ARRB2 deficiency (global knockout) in mice causes elevated saline intake at baseline and exacerbated fluid intake and pressor response under DOCA-salt hypertension, indicating that ARRB2 counterbalances canonical GPCR signaling to regulate fluid homeostasis and blood pressure in salt-sensitive hypertension. ARRB1 knockout did not produce the same saline intake phenotype, indicating ARRB2 specificity.","method":"Global Arrb2 knockout and Arrb1 knockout mice, 2-bottle choice paradigm, telemetric blood pressure measurement, DOCA-salt hypertension model, plasma sodium measurement","journal":"Hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with defined physiological phenotype and isoform-specificity control (ARRB1 KO); single lab","pmids":["36215165"],"is_preprint":false},{"year":2023,"finding":"Deletion of Arrb2 in mice causes hyperactivation of Akt-mTOR signaling in the hippocampus, resulting in decreased autophagy (reduced LC3B), and mitochondrial dysfunction characterized by reduced membrane potential and ATP production and increased ROS in hippocampal neurons.","method":"Arrb2-/- mice, western blot for LC3B, Akt, mTOR and downstream targets, mitochondrial membrane potential assay, ATP measurement, ROS detection in hippocampal neurons","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with multiple molecular and cellular readouts; single lab, no rescue experiment","pmids":["36796753"],"is_preprint":false},{"year":2025,"finding":"REG3A functions as an exocytosis protein that binds to GPR54, increasing membrane localization of GPR54, which then engages ARRB2 as a scaffolding molecule to activate ERK1/2 signaling and suppress gemcitabine-induced apoptosis in pancreatic cancer cells.","method":"RNA-seq, PPI analysis, Co-IP for REG3A-GPR54 and GPR54-ARRB2 interactions, ARRB2 siRNA, GPR54 antagonist KP234, Reg3g knockout mice, in vitro and in vivo gemcitabine resistance assays","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP-based complex identification with genetic and pharmacological epistasis in vitro and in vivo; single lab","pmids":["40935160"],"is_preprint":false},{"year":2022,"finding":"ARRB2 is the direct target of miR-361, and the lncRNA GATA3-AS1 acts as a ceRNA to sequester miR-361, thereby indirectly upregulating ARRB2. ARRB2 activates the Src/Akt pathway in endometrial carcinoma cells, promoting invasion and migration.","method":"Dual-luciferase reporter assay and RNA immunoprecipitation (RIP) for miR-361/ARRB2 interaction and GATA3-AS1/miR-361 interaction; western blot for Src/Akt; ARRB2 overexpression/knockdown; in vivo xenograft assays","journal":"Journal of molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — luciferase and RIP confirm miR-361 targeting of ARRB2, but the ARRB2-Src/Akt pathway link relies on single western blot readout without direct ARRB2-Src binding evidence","pmids":["35788718"],"is_preprint":false},{"year":2025,"finding":"ARRB2 stabilizes CDC25A mRNA through IGF2BP1 in an m6A-dependent manner; CDC25A in turn promotes FOXO3 phosphorylation and cytoplasmic retention, enabling Snail1 transcription and EMT, thereby facilitating cervical cancer proliferation and metastasis.","method":"RNA immunoprecipitation (RIP) for ARRB2-IGF2BP1-CDC25A mRNA complex, m6A methylation assay, ARRB2 and CDC25A knockdown/overexpression, western blot, in vivo tumor models","journal":"NPJ precision oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — RIP demonstrates complex formation, but mechanistic dissection of ARRB2-IGF2BP1-mRNA interaction is limited to single-lab functional readouts without reconstitution","pmids":["40119070"],"is_preprint":false},{"year":2025,"finding":"METTL3-dependent m6A methylation of ARRB2 mRNA upregulates ARRB2 protein expression in intrahepatic cholangiocarcinoma; elevated ARRB2 then promotes YAP nuclear translocation and activates the Raf-MEK-ERK signaling axis to drive ICC malignant progression and resistance to pemigatinib.","method":"m6A methylation assay, METTL3 overexpression/knockdown, ARRB2 knockdown, YAP nuclear fractionation, western blot for Raf-MEK-ERK, pemigatinib resistance assays in vitro and in vivo","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional epistasis with multiple readouts but mechanistic link between ARRB2 and YAP nuclear translocation is based on single-lab western blot/fractionation without direct binding data","pmids":["41986296"],"is_preprint":false},{"year":2025,"finding":"In Treg cells, β2-AR agonist terbutaline increases ARRB2 expression and phospho-ERK1/2 levels; ARRB2 gene silencing reduces this pERK1/2 increase and impairs TGF-β and IL-10 production, while ARRB2 overexpression enhances these effects. Adoptive transfer of ARRB2-overexpressing Treg cells into CIA mice reduces joint inflammation and Th17 cytokine production, placing the β2-AR/ARRB2/ERK1/2 axis as a non-canonical signaling pathway that enhances Treg suppressive function.","method":"ARRB2 siRNA and overexpression in iTreg cells, western blot for pERK1/2, ELISA for TGF-β and IL-10, Teff proliferation suppression assay, adoptive transfer into CIA mice, clinical arthritis scoring, cytokine measurement","journal":"Arthritis research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with in vivo adoptive transfer rescue; single lab with multiple orthogonal readouts","pmids":["41107955"],"is_preprint":false},{"year":2025,"finding":"Cryo-EM structures of mGluR8 with β-arr1 and molecular dynamics simulations reveal that β-arrestin (including β-arr2 as part of mGluR/β-arr1/β-arr2 megacomplexes identified by combinatorial mutagenesis) couples to dimeric family C GPCRs with 2:1 or 2:2 stoichiometry via 'tail' and 'core' interactions, and that β-arr-bound mGluR8 adopts a transducer-specific active state; steric interaction with both subunits and lipid bilayer supports a desensitization mechanism.","method":"Cryo-EM structural determination, single-molecule pulldown stoichiometry assay, single-molecule FRET, molecular dynamics simulations, combinatorial mutagenesis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — cryo-EM structure + MD + smFRET + mutagenesis is rigorous, but β-arr2-specific findings (megacomplex identification) are limited within a predominantly β-arr1-focused study; preprint not yet peer-reviewed","pmids":[],"is_preprint":true},{"year":2026,"finding":"In hepatocytes, Arrb2 remodels bile acid metabolism by upregulating Cyp7a1, increasing levels of the bile acid metabolite 6-ketoLCA; 6-ketoLCA in turn activates TGR5 on macrophages to promote M2 polarization, thereby attenuating hepatic ischemia-reperfusion injury. The drug dutasteride was identified as an enhancer of the Arrb2 promoter that upregulates Arrb2 expression.","method":"Hepatocyte-specific and global Arrb2 models, 70% hepatic I/R mouse model, bile acid profiling, macrophage polarization assays (M1/M2 markers), TGR5 functional experiments, dutasteride promoter activity assay","journal":"Hepatology communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional in vivo and in vitro data with metabolite identification; mechanistic links between ARRB2, Cyp7a1, and 6-ketoLCA are correlative rather than directly reconstituted; single lab","pmids":["42043875"],"is_preprint":false}],"current_model":"ARRB2 (β-arrestin 2) is a multifunctional cytoplasmic scaffolding protein that negatively regulates GPCR signaling by physically assembling multi-protein complexes at activated receptors; it suppresses NF-κB inflammatory signaling by recruiting TRAF6 and PP2A to the DRD5 receptor complex, sequesters JNK in the cytoplasm to dampen mu-opioid receptor-mediated JNK activation in a ligand-specific manner, participates in AKT/PDE4 complexes in lipid rafts to modulate cAMP levels, scaffolds ERK1/2 and AKT to promote endothelial progenitor cell angiogenic functions and prostate cancer MAPK signaling, acts as a negative regulator of the NLRP3 inflammasome (competed away by SUMOylated TRPC1), and mediates fluid homeostasis and blood pressure regulation downstream of GPCRs in salt-sensitive hypertension, while its expression is itself regulated transcriptionally by Egr1 (repressed via WDR4-DDX20) and by STAT5B, and post-transcriptionally by m6A methylation and multiple miRNAs."},"narrative":{"mechanistic_narrative":"ARRB2 (β-arrestin 2) is a multifunctional cytoplasmic scaffolding protein that assembles multi-protein complexes downstream of activated G protein-coupled receptors to both dampen and redirect signaling [PMID:32035036]. Structurally, it couples to dimeric family C GPCRs through combined 'tail' and 'core' interactions, supporting receptor desensitization. As a negative regulator of inflammatory signaling, ARRB2 is recruited together with TRAF6 and PP2A to the DRD5 receptor via specific motifs, where it impairs TRAF6-mediated NF-κB activation and pro-inflammatory gene expression [PMID:32035036], and it binds the NLRP3 inflammasome to suppress its activation until competed away by SUMOylated TRPC1 [PMID:39921112]. ARRB2 also sequesters JNK in the cytoplasm of sensory neurons to restrain mu-opioid receptor-driven JNK signaling in a ligand-specific manner [PMID:22491351], and participates in an AKT/ARRB2/PDE4 lipid-raft complex that degrades cAMP [PMID:26549736]. Beyond suppression, ARRB2 directly binds and activates ERK1/2 and AKT to scaffold proliferative and pro-survival MAPK signaling across endothelial progenitor cells, prostate cancer, and GPR54/KISS1R-dependent neuroprotection [PMID:32863967, PMID:38341429, PMID:33989759]. Physiologically, ARRB2 counterbalances GPCR signaling to control fluid homeostasis and blood pressure in salt-sensitive hypertension in an isoform-specific manner [PMID:36215165], and its loss hyperactivates Akt-mTOR signaling with impaired autophagy and mitochondrial function [PMID:36796753]. ARRB2 expression is itself tightly controlled, being transcriptionally driven by STAT5B and Egr1 (the latter repressed via WDR4-DDX20) [PMID:38341429, PMID:37783676].","teleology":[{"year":1994,"claim":"Establishing the physical genomic location of human ARRB2 anchored it as a discrete gene available for functional study.","evidence":"FISH mapping to chromosome band 17p13","pmids":["7695743"],"confidence":"Medium","gaps":["No functional or mechanistic information conveyed","Does not address protein activity or partners"]},{"year":2012,"claim":"Resolved how ARRB2 shapes opioid receptor outputs by showing it spatially confines JNK signaling, explaining ligand-biased behavioral phenotypes.","evidence":"β-arr2 knockout mice with JNK inhibitor epistasis and immunofluorescence in DRG neurons, plus morphine/fentanyl ligand controls","pmids":["22491351"],"confidence":"High","gaps":["Direct ARRB2-JNK binding interface not mapped","Mechanism of cytoplasmic sequestration not biochemically defined"]},{"year":2015,"claim":"Identified ARRB2 as a structural component of a lipid-raft cAMP-degrading machine, linking it to control of NF-κB-driven cytokine production.","evidence":"Co-IP of AKT/ARRB2/PDE4 complex, lipid raft fractionation, and miR-150 luciferase targeting assay","pmids":["26549736"],"confidence":"Medium","gaps":["Complex not reconstituted in vitro","Stoichiometry and direct contacts within the trimer unresolved"]},{"year":2020,"claim":"Defined a receptor-templated mechanism for ARRB2's anti-inflammatory role, showing DRD5 recruits ARRB2 and PP2A to inactivate TRAF6-NF-κB signaling.","evidence":"Reciprocal Co-IP with EFD/IYX(X)I/L motif mutagenesis plus macrophage and in vivo sepsis/meningitis models","pmids":["32035036"],"confidence":"High","gaps":["How ARRB2 directs PP2A activity onto TRAF6 substrates not detailed","Generalizability to other GPCR-TRAF6 axes untested"]},{"year":2021,"claim":"Showed ARRB2 acts as a positive scaffold for ERK1/2 and AKT, broadening its role from signaling brake to pro-proliferative/pro-survival driver across cell types.","evidence":"Co-IP of ARRB2-ERK1/2 and ARRB2-AKT plus gain/loss-of-function in EPCs and KISS1R-dependent neuroprotection models in vivo","pmids":["32863967","33989759"],"confidence":"Medium","gaps":["Direct binding interfaces with ERK1/2 and AKT not mapped","Context that switches ARRB2 between inhibitory and activating modes unclear"]},{"year":2022,"claim":"Demonstrated an isoform-specific physiological function for ARRB2 in counterbalancing GPCR signaling for fluid and blood pressure homeostasis.","evidence":"Global Arrb2 and Arrb1 knockout mice with 2-bottle choice, telemetric BP, and DOCA-salt hypertension model","pmids":["36215165"],"confidence":"Medium","gaps":["Specific GPCRs/tissues mediating the phenotype not identified","Molecular mechanism downstream of ARRB2 in this axis undefined"]},{"year":2023,"claim":"Connected ARRB2 levels to disease-relevant signaling rewiring, showing both that elevated ARRB2 drives pulmonary hypertension phenotypes and that ARRB2 loss deranges Akt-mTOR/autophagy in neurons.","evidence":"BMPR2 KO + ARRB2 reduction genetic epistasis in mouse/human PASMC; Arrb2-/- mice with autophagy and mitochondrial readouts in hippocampus","pmids":["36744494","36796753"],"confidence":"High","gaps":["Direct ARRB2 effectors in the AKT-GSK3β-β-catenin cascade not defined","Neuronal phenotype lacks rescue experiment"]},{"year":2023,"claim":"Defined transcriptional control of ARRB2, identifying an Egr1-driven program repressed by a WDR4-DDX20 adaptor module.","evidence":"Co-IP of WDR4-DDX20-Egr1, fractionation, Egr1-ARRB2 luciferase reporter in bladder cancer cells","pmids":["37783676"],"confidence":"Medium","gaps":["Direct Egr1 binding site on ARRB2 promoter not finely mapped","Whether this regulation operates outside bladder cancer untested"]},{"year":2024,"claim":"Linked an upstream transcription factor to ARRB2's pro-tumorigenic MAPK scaffolding, showing STAT5B drives ARRB2 to potentiate ERK1/2.","evidence":"ChIP-qPCR and luciferase for STAT5B-ARRB2 promoter binding plus ARRB2-ERK1/2 Co-IP and prostate cancer in vivo assays","pmids":["38341429"],"confidence":"Medium","gaps":["How ARRB2 enhances ERK1/2 phosphorylation mechanistically unclear","Receptor input upstream of this scaffold not defined"]},{"year":2025,"claim":"Refined the structural basis for ARRB2 coupling to family C GPCRs and its competitive displacement at the inflammasome.","evidence":"Cryo-EM/smFRET/MD of mGluR-β-arrestin megacomplexes (preprint); Co-IP and domain mapping of TRPC1-ARRB2 versus NLRP3-ARRB2 in stroke models","pmids":["39921112"],"confidence":"Medium","gaps":["β-arr2-specific structural detail limited within a β-arr1-focused study","How SUMO-driven competition is regulated in vivo not fully resolved"]},{"year":2025,"claim":"Expanded ARRB2's reach into post-transcriptional and metabolic regulation, with m6A-dependent control of ARRB2 and ARRB2-mediated effects on lipid and bile acid metabolism and immune cell function.","evidence":"m6A assays, RIP, METTL3/IGF2BP1 manipulation, AMPK pathway readouts, metabolomics, and Treg adoptive transfer across multiple disease models","pmids":["41986296","40119070","33871024","41107955"],"confidence":"Low","gaps":["Many links (ARRB2-YAP, ARRB2-CDC25A mRNA) rest on single-lab functional readouts without reconstitution","Direct biochemical contacts in these complexes not established"]},{"year":null,"claim":"It remains unresolved what determines whether ARRB2 acts as a signaling brake (NF-κB, JNK, NLRP3) versus a positive scaffold (ERK1/2, AKT) at a given receptor and cellular context.","evidence":"No single study in the corpus reconciles the inhibitory and activating modes mechanistically","pmids":[],"confidence":"Low","gaps":["No structural or biochemical switch identified","Receptor- and cell-type-specific partner selection rules undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,5,11,1,9]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,9,0]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,19]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,11,19]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,9,18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,5]}],"complexes":["AKT/ARRB2/PDE4 complex","DRD5-ARRB2-TRAF6-PP2A complex","NLRP3/ARRB2 complex"],"partners":["TRAF6","PP2A","PDE4","AKT","ERK1/2","JNK","NLRP3","TRPC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P32121","full_name":"Beta-arrestin-2","aliases":["Arrestin beta-2","Non-visual arrestin-3"],"length_aa":409,"mass_kda":46.1,"function":"Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes (PubMed:37209686, PubMed:38175886). During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Two different modes of arrestin-mediated internalization occur. Class A receptors, like ADRB2, OPRM1, ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the plasma membrane and undergo rapid recycling. Class B receptors, like AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptors, for extended periods of time. Receptor resensitization then requires that receptor-bound arrestin is removed so that the receptor can be dephosphorylated and returned to the plasma membrane. Mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21. Involved in internalization of P2RY1, P2RY4, P2RY6 and P2RY11 and ATP-stimulated internalization of P2RY2. Involved in phosphorylation-dependent internalization of OPRD1 and subsequent recycling or degradation. Involved in ubiquitination of IGF1R. Beta-arrestins function as multivalent adapter proteins that can switch the GPCR from a G-protein signaling mode that transmits short-lived signals from the plasma membrane via small molecule second messengers and ion channels to a beta-arrestin signaling mode that transmits a distinct set of signals that are initiated as the receptor internalizes and transits the intracellular compartment. Acts as a signaling scaffold for MAPK pathways such as MAPK1/3 (ERK1/2) and MAPK10 (JNK3). ERK1/2 and JNK3 activated by the beta-arrestin scaffold are largely excluded from the nucleus and confined to cytoplasmic locations such as endocytic vesicles, also called beta-arrestin signalosomes. Acts as a signaling scaffold for the AKT1 pathway. GPCRs for which the beta-arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is inhibited by the other respective beta-arrestin form (reciprocal regulation). Increases ERK1/2 signaling in AGTR1- and AVPR2-mediated activation (reciprocal regulation). Involved in CCR7-mediated ERK1/2 signaling involving ligand CCL19. Is involved in type-1A angiotensin II receptor/AGTR1-mediated ERK activity. Is involved in type-1A angiotensin II receptor/AGTR1-mediated MAPK10 activity. Is involved in dopamine-stimulated AKT1 activity in the striatum by disrupting the association of AKT1 with its negative regulator PP2A. Involved in AGTR1-mediated chemotaxis. Appears to function as signaling scaffold involved in regulation of MIP-1-beta-stimulated CCR5-dependent chemotaxis. Involved in attenuation of NF-kappa-B-dependent transcription in response to GPCR or cytokine stimulation by interacting with and stabilizing CHUK. Suppresses UV-induced NF-kappa-B-dependent activation by interacting with CHUK. The function is promoted by stimulation of ADRB2 and dephosphorylation of ARRB2. Involved in p53/TP53-mediated apoptosis by regulating MDM2 and reducing the MDM2-mediated degradation of p53/TP53. May serve as nuclear messenger for GPCRs. Upon stimulation of OR1D2, may be involved in regulation of gene expression during the early processes of fertilization. Also involved in regulation of receptors other than GPCRs. Involved in endocytosis of TGFBR2 and TGFBR3 and down-regulates TGF-beta signaling such as NF-kappa-B activation. Involved in endocytosis of low-density lipoprotein receptor/LDLR. Involved in endocytosis of smoothened homolog/Smo, which also requires GRK2. Involved in endocytosis of SLC9A5. Involved in endocytosis of ENG and subsequent TGF-beta-mediated ERK activation and migration of epithelial cells. Involved in Toll-like receptor and IL-1 receptor signaling through the interaction with TRAF6 which prevents TRAF6 autoubiquitination and oligomerization required for activation of NF-kappa-B and JUN (PubMed:26839314). Involved in insulin resistance by acting as insulin-induced signaling scaffold for SRC, AKT1 and INSR. Involved in regulation of inhibitory signaling of natural killer cells by recruiting PTPN6 and PTPN11 to KIR2DL1. Involved in IL8-mediated granule release in neutrophils. Involved in the internalization of the atypical chemokine receptor ACKR3. Acts as an adapter protein coupling FFAR4 receptor to specific downstream signaling pathways, as well as mediating receptor endocytosis (PubMed:22282525, PubMed:23809162). During the activation step of NLRP3 inflammasome, directly associates with NLRP3 leading to inhibition of pro-inflammatory cytokine release and inhibition of inflammation (PubMed:23809162)","subcellular_location":"Cytoplasm; Nucleus; Cell membrane; Membrane, clathrin-coated pit; Cytoplasmic vesicle","url":"https://www.uniprot.org/uniprotkb/P32121/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARRB2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ARRB2","total_profiled":1310},"omim":[{"mim_id":"619768","title":"ARRESTIN DOMAIN-CONTAINING PROTEIN 1; ARRDC1","url":"https://www.omim.org/entry/619768"},{"mim_id":"611302","title":"SPASTIC ATAXIA 2, AUTOSOMAL RECESSIVE; SPAX2","url":"https://www.omim.org/entry/611302"},{"mim_id":"606409","title":"ITCHY E3 UBIQUITIN PROTEIN LIGASE; ITCH","url":"https://www.omim.org/entry/606409"},{"mim_id":"604936","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 1; KIR2DL1","url":"https://www.omim.org/entry/604936"},{"mim_id":"603823","title":"FREE FATTY ACID RECEPTOR 2; FFAR2","url":"https://www.omim.org/entry/603823"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":249.0},{"tissue":"lymphoid tissue","ntpm":157.8}],"url":"https://www.proteinatlas.org/search/ARRB2"},"hgnc":{"alias_symbol":["BARR2","DKFZp686L0365"],"prev_symbol":["ARR2"]},"alphafold":{"accession":"P32121","domains":[{"cath_id":"2.60.40.840","chopping":"7-173","consensus_level":"high","plddt":88.348,"start":7,"end":173},{"cath_id":"2.60.40.640","chopping":"183-344","consensus_level":"high","plddt":92.2206,"start":183,"end":344}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P32121","model_url":"https://alphafold.ebi.ac.uk/files/AF-P32121-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P32121-F1-predicted_aligned_error_v6.png","plddt_mean":83.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARRB2","jax_strain_url":"https://www.jax.org/strain/search?query=ARRB2"},"sequence":{"accession":"P32121","fasta_url":"https://rest.uniprot.org/uniprotkb/P32121.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P32121/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P32121"}},"corpus_meta":[{"pmid":"32035036","id":"PMC_32035036","title":"Dopamine Uses the DRD5-ARRB2-PP2A Signaling Axis to Block the TRAF6-Mediated NF-κB Pathway and Suppress Systemic Inflammation.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32035036","citation_count":77,"is_preprint":false},{"pmid":"12654674","id":"PMC_12654674","title":"Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-beta-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000.","date":"2003","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/12654674","citation_count":58,"is_preprint":false},{"pmid":"26549736","id":"PMC_26549736","title":"MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway.","date":"2015","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26549736","citation_count":54,"is_preprint":false},{"pmid":"36744494","id":"PMC_36744494","title":"Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36744494","citation_count":44,"is_preprint":false},{"pmid":"7695743","id":"PMC_7695743","title":"Chromosome mapping of the human arrestin (SAG), beta-arrestin 2 (ARRB2), and beta-adrenergic receptor kinase 2 (ADRBK2) genes.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7695743","citation_count":41,"is_preprint":false},{"pmid":"33989759","id":"PMC_33989759","title":"Kisspeptin-54 attenuates oxidative stress and neuronal apoptosis in early brain injury after subarachnoid hemorrhage in rats via GPR54/ARRB2/AKT/GSK3β signaling pathway.","date":"2021","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33989759","citation_count":36,"is_preprint":false},{"pmid":"22491351","id":"PMC_22491351","title":"Evidence that behavioral phenotypes of morphine in β-arr2-/- mice are due to the unmasking of JNK signaling.","date":"2012","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22491351","citation_count":28,"is_preprint":false},{"pmid":"19049562","id":"PMC_19049562","title":"The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia.","date":"2008","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19049562","citation_count":22,"is_preprint":false},{"pmid":"34111458","id":"PMC_34111458","title":"miRNAs through β-ARR2/p-ERK1/2 pathway regulate the VSMC proliferation and migration.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34111458","citation_count":21,"is_preprint":false},{"pmid":"33367479","id":"PMC_33367479","title":"ARRB2 promotes colorectal cancer growth through triggering WTAP.","date":"2021","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/33367479","citation_count":20,"is_preprint":false},{"pmid":"24635845","id":"PMC_24635845","title":"The genetic variation of ARRB2 is associated with late-onset Alzheimer's disease in Han Chinese.","date":"2014","source":"Current Alzheimer research","url":"https://pubmed.ncbi.nlm.nih.gov/24635845","citation_count":20,"is_preprint":false},{"pmid":"33871024","id":"PMC_33871024","title":"Arrb2 causes hepatic lipid metabolism disorder via AMPK pathway based on metabolomics in alcoholic fatty liver.","date":"2021","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33871024","citation_count":16,"is_preprint":false},{"pmid":"32863967","id":"PMC_32863967","title":"Arrb2 promotes endothelial progenitor cell-mediated postischemic neovascularization.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32863967","citation_count":13,"is_preprint":false},{"pmid":"36215165","id":"PMC_36215165","title":"ARRB2 (β-Arrestin-2) Deficiency Alters Fluid Homeostasis and Blood Pressure Regulation.","date":"2022","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/36215165","citation_count":11,"is_preprint":false},{"pmid":"38341429","id":"PMC_38341429","title":"PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38341429","citation_count":11,"is_preprint":false},{"pmid":"22472784","id":"PMC_22472784","title":"Association study of the β-arrestin 2 gene (ARRB2) with opioid and cocaine dependence in a European-American population.","date":"2012","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22472784","citation_count":10,"is_preprint":false},{"pmid":"32471349","id":"PMC_32471349","title":"Repeated social defeat promotes persistent inflammatory changes in splenic myeloid cells; decreased expression of β-arrestin-2 (ARRB2) and increased expression of interleukin-6 (IL-6).","date":"2020","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32471349","citation_count":9,"is_preprint":false},{"pmid":"33783060","id":"PMC_33783060","title":"β-Arrestin 2 (ARRB2) Polymorphism is Associated With Adverse Consequences of Chronic Heroin Use.","date":"2021","source":"The American journal on addictions","url":"https://pubmed.ncbi.nlm.nih.gov/33783060","citation_count":8,"is_preprint":false},{"pmid":"35788718","id":"PMC_35788718","title":"LncRNA GATA3-AS1 promoted invasion and migration in human endometrial carcinoma by regulating the miR-361/ARRB2 axis.","date":"2022","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35788718","citation_count":7,"is_preprint":false},{"pmid":"39921112","id":"PMC_39921112","title":"Microglia TRPC1 SUMOylation drives neuroinflammation after stroke by modulating NLRP3 activity via increasing TRPC1 interaction with ARRB2.","date":"2025","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39921112","citation_count":7,"is_preprint":false},{"pmid":"37783676","id":"PMC_37783676","title":"WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2.","date":"2023","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/37783676","citation_count":7,"is_preprint":false},{"pmid":"41107955","id":"PMC_41107955","title":"Treg cells mitigate inflammatory responses and symptoms via β2-AR/β-Arr2/ERK signaling in an experimental rheumatoid arthritis.","date":"2025","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41107955","citation_count":6,"is_preprint":false},{"pmid":"36284990","id":"PMC_36284990","title":"The Comprehensive Analysis of Hub Gene ARRB2 in Prostate Cancer.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/36284990","citation_count":5,"is_preprint":false},{"pmid":"36796753","id":"PMC_36796753","title":"Deletion of Arrb2 Down-regulates Autophagy in the Mouse Hippocampus via Akt-mTOR Pathway Activation.","date":"2023","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36796753","citation_count":4,"is_preprint":false},{"pmid":"40935160","id":"PMC_40935160","title":"REG3A promotes gemcitabine resistance in pancreatic cancer via the GPR54/ARRB2/ERK1/2 ligand-directed signaling pathway.","date":"2025","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40935160","citation_count":3,"is_preprint":false},{"pmid":"38833209","id":"PMC_38833209","title":"MiR-483-3p promotes dental pulp stem cells osteogenic differentiation via the MAPK signaling pathway by targeting ARRB2.","date":"2024","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/38833209","citation_count":3,"is_preprint":false},{"pmid":"40119070","id":"PMC_40119070","title":"ARRB2 promotes cervical cancer progression via stabilizing CDC25A mRNA through m6A-IGF2BP1-dependent manner.","date":"2025","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40119070","citation_count":2,"is_preprint":false},{"pmid":"40428426","id":"PMC_40428426","title":"Systems Genetics Reveals the Gene Regulatory Mechanisms of Arrb2 in the Development of Autism Spectrum Disorders.","date":"2025","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/40428426","citation_count":2,"is_preprint":false},{"pmid":"39775075","id":"PMC_39775075","title":"Dissemination of arr-2 and arr-3 is associated with class 1 integrons in Klebsiella pneumoniae clinical isolates from Portugal.","date":"2025","source":"Medical microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39775075","citation_count":2,"is_preprint":false},{"pmid":"37628689","id":"PMC_37628689","title":"Exploring the Binding Affinity of the ARR2 GARP DNA Binding Domain via Comparative Methods.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37628689","citation_count":1,"is_preprint":false},{"pmid":"39545854","id":"PMC_39545854","title":"Interactive effects of ARRB2 and CHRNA5 genetic polymorphisms on cognitive function in Chinese male methamphetamine use disorder patients.","date":"2024","source":"The American journal on addictions","url":"https://pubmed.ncbi.nlm.nih.gov/39545854","citation_count":1,"is_preprint":false},{"pmid":"41986296","id":"PMC_41986296","title":"N6-methyladenosine-mediated up-regulation of ARRB2 regulates intrahepatic cholangiocarcinoma malignant progression and pemigatinib resistance through MAPK and Hippo signaling pathways.","date":"2026","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41986296","citation_count":0,"is_preprint":false},{"pmid":"40973140","id":"PMC_40973140","title":"A Preliminary Prospective Study on the Association of Polymorphisms in BDNF, ARRB2 and KCNJ6 and Response to Fentanyl for Pain Management in Advanced Cancer.","date":"2025","source":"Cancer control : journal of the Moffitt Cancer Center","url":"https://pubmed.ncbi.nlm.nih.gov/40973140","citation_count":0,"is_preprint":false},{"pmid":"41418454","id":"PMC_41418454","title":"An explainable predictive machine learning model reveals ARRB2 as a key gene in post-traumatic stress disorder: A GEO database study.","date":"2025","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/41418454","citation_count":0,"is_preprint":false},{"pmid":"42043875","id":"PMC_42043875","title":"Arrb2 in hepatocytes promotes M2 macrophage polarization, ameliorates hepatic ischemia-reperfusion injury through upregulating metabolite 6-ketoLCA.","date":"2026","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/42043875","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.03.636340","title":"Structural Diversity and Dynamics of Metabotropic Glutamate Receptor/Beta-Arrestin Coupling","date":"2025-02-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.03.636340","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.29.649777","title":"Mechanistic basis for GPCR phosphorylation-dependent allosteric signaling specificity of  <i>β</i>  -arrestin 1 and 2","date":"2025-05-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.29.649777","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.30.25330542","title":"Preterm birth and the risk of infant respiratory syncytial virus associated acute lower respiratory infection in Australia’s Northern Territory","date":"2025-06-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.30.25330542","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.24.666383","title":"Revealing the nervous system requirements of Alzheimer’s disease risk genes in  <i>Drosophila</i>","date":"2025-07-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.24.666383","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":23723,"output_tokens":6360,"usd":0.083284,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15147,"output_tokens":4005,"usd":0.08793,"stage2_stop_reason":"end_turn"},"total_usd":0.171214,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"Dopamine receptor DRD5, via EFD and IYX(X)I/L motifs in its C-terminal and IC3 loop, directly recruits both TRAF6 and ARRB2 to form a multi-protein complex also containing TAK1, IKKs, and PP2A. Within this complex, ARRB2 acts as a negative regulator of TRAF6, and the DA-DRD5-ARRB2-PP2A signaling axis impairs TRAF6-mediated activation of NF-κB and expression of pro-inflammatory genes.\",\n      \"method\": \"Co-immunoprecipitation, domain-mapping mutagenesis (EFD and IYX(X)I/L motif mutations), in vivo mouse models (S. aureus sepsis and meningitis), macrophage knockdown/overexpression experiments\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with domain-mapping mutagenesis, multiple orthogonal cellular and in vivo functional assays in a single focused study\",\n      \"pmids\": [\"32035036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ARRB2 directly participates in an AKT/ARRB2/PDE4 trimeric complex that is recruited into the lipid raft to degrade cAMP. miR-150 represses ARRB2 (and PDE4) expression and prevents this complex from entering the lipid raft, thereby interrupting cAMP degradation and inhibiting IL-2 and TNF production via the NF-κB pathway.\",\n      \"method\": \"miRNA overexpression with western blot, RT-PCR; lipid raft fractionation; co-immunoprecipitation of AKT/ARRB2/PDE4 complex; luciferase reporter assay for miR-150 targeting of ARRB2\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple orthogonal methods (Co-IP, fractionation, reporter assay) in a single lab; complex membership established but reconstitution not performed\",\n      \"pmids\": [\"26549736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of BMPR2 in pulmonary artery smooth muscle cells (PASMC) causes upregulation of ARRB2 via a pERK1/2-pP38-pSMAD2/3 cascade. Elevated ARRB2 in turn activates pAKT-mediated inactivation of GSK3-beta, drives CTNNB1 (β-catenin) nuclear translocation, and reduces RHOA and RAC1, producing a hypocontractile, hyperproliferative phenotype. Genetic reduction of ARRB2 in BMPR2-deficient PASMC restores normal signaling and contractility and prevents persistent pulmonary hypertension in mice with inducible SMC-specific BMPR2 loss.\",\n      \"method\": \"SMC-specific Bmpr2 knockout mice, siRNA knockdown in human PASMC, PASMC from PAH patients with BMPR2 mutation, western blot for pERK1/2, pP38, pSMAD2/3, ARRB2, pAKT, GSK3β, β-catenin, RHOA, RAC1; echocardiography, RVSP measurement, proliferation/contractility assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (BMPR2 KO + ARRB2 reduction rescue) with multiple orthogonal cellular and in vivo phenotypic readouts across mouse and human PASMC models\",\n      \"pmids\": [\"36744494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"β-arrestin 2 (ARRB2/β-arr2) sequesters JNK in the cytoplasm of dorsal root ganglion neurons; deletion of β-arr2 results in altered intracellular distribution of JNK and phospho-cJun, and unmasks morphine-specific (but not fentanyl-specific) activation of the JNK cascade. JNK inhibitors reverse the enhanced analgesia, reduced locomotion, and enhanced sensitization phenotypes of β-arr2-/- mice to wild-type levels, placing ARRB2 as a negative regulator of JNK signaling downstream of mu-opioid receptor activation.\",\n      \"method\": \"β-arr2 knockout mice, pharmacological JNK inhibitors (two compounds), immunofluorescence for phospho-cJun nuclear localization in DRG neurons, behavioral assays (analgesia, locomotion, sensitization), PKC inhibitor comparison\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with pharmacological epistasis using two independent JNK inhibitors and multiple behavioral readouts; ligand-specificity controls (morphine vs. fentanyl) strengthen mechanism\",\n      \"pmids\": [\"22491351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human ARRB2 gene was chromosomally mapped to band 17p13 by fluorescence in situ hybridization (FISH), establishing its physical genomic location.\",\n      \"method\": \"Fluorescence in situ hybridization (FISH) on human chromosomes\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cytogenetic mapping by FISH, single lab, single method\",\n      \"pmids\": [\"7695743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In endothelial progenitor cells (EPCs), ARRB2 physically interacts with and activates ERK1/2 and AKT signaling pathways, promoting EPC proliferation, migration, adhesion, tube formation, and protection from hypoxia-induced apoptosis. ARRB2-overexpressing EPCs transplanted into ischemic hind-limb mice showed significantly improved blood flow restoration and capillary density.\",\n      \"method\": \"Lentivirus-mediated overexpression and knockdown of Arrb2 in EPCs, Co-IP for ARRB2-ERK1/2 and ARRB2-AKT interaction, proliferation/migration/tube formation assays, Arrb2-deficient mice with hind-limb ischemia model, laser Doppler measurements, histology\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP plus multiple functional assays plus in vivo rescue, single lab\",\n      \"pmids\": [\"32863967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARRB2 induces hepatic lipid metabolism disorders and lipid accumulation through the AMPK pathway in alcoholic fatty liver, increasing both fatty acid and cholesterol synthesis; knockdown of Arrb2 in mouse liver in vivo and in AML-12 cells in vitro reversed lipid accumulation, and LC-MS metabolomics identified primary bile acids as the most significantly altered hepatic lipid metabolites.\",\n      \"method\": \"In vivo Arrb2 knockdown in AFL mice, siRNA and pEX3-Arrb2 overexpression in AML-12 cells, western blot for AMPK pathway proteins, LC-MS metabolomics\",\n      \"journal\": \"Clinical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro loss/gain-of-function with AMPK pathway readout plus metabolomics; single lab\",\n      \"pmids\": [\"33871024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARRB2 promotes colorectal cancer cell growth, motility, and apoptosis resistance by regulating the expression of Wilms tumor 1 associated protein (WTAP); knockdown of ARRB2 decreased WTAP expression and attenuated cancer pathway activation.\",\n      \"method\": \"ARRB2 knockdown in CRC cell lines, western blot, AOM/DSS mouse model, cell proliferation/migration/apoptosis assays\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single KD approach; mechanism linking ARRB2 to WTAP not biochemically defined at the protein-protein level\",\n      \"pmids\": [\"33367479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPR54 (KISS1R) requires ARRB2 as a functional adaptor to mediate neuroprotective effects of kisspeptin-54 (KP54); ARRB2 siRNA knockout offsets the neuroprotective effects of KP54, and the pathway operates through ARRB2/AKT/GSK3β to reduce oxidative stress and neuronal apoptosis after subarachnoid hemorrhage.\",\n      \"method\": \"ARRB2 siRNA intracerebroventricular administration in rats, GPR54 antagonist (KP234), western blot, immunofluorescence, behavioral tests, TUNEL/Fluoro-Jade C staining in SAH rat model\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (siRNA) and pharmacological epistasis in a well-defined in vivo model with multiple orthogonal phenotypic readouts; single lab\",\n      \"pmids\": [\"33989759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SUMOylated TRPC1 in microglia facilitates interaction between TRPC1 and ARRB2; normally ARRB2 binds to NLRP3 to suppress inflammasome activation. SUMOylation of TRPC1 disrupts the NLRP3/ARRB2 complex by competing for ARRB2 binding (ARRB2 binds residues 46–61 of TRPC1 N-terminus), thereby activating NLRP3 signaling and exacerbating neuroinflammation after stroke.\",\n      \"method\": \"Co-IP for TRPC1-ARRB2 and NLRP3-ARRB2 interaction, TRPC1 SUMOylation-deficient mice, MCAO/R model, oxygen-glucose deprivation/regeneration in vitro, domain mapping (TRPC1 residues 46–61), western blot, behavior and infarct volume measurements\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping and genetic loss-of-function model; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"39921112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"WDR4 acts as an adaptor that promotes nuclear localization of DDX20 and bridges DDX20 with transcription factor Egr1, thereby inhibiting Egr1-promoted transcriptional expression of ARRB2. This WDR4-mediated transcriptional suppression of ARRB2 contributes to bladder cancer progression and lymph node metastasis.\",\n      \"method\": \"Co-IP for WDR4-DDX20-Egr1 complex, subcellular fractionation for DDX20 nuclear localization, luciferase reporter for Egr1-driven ARRB2 transcription, WDR4 knockdown/overexpression in bladder cancer cells, in vivo metastasis models, IHC\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP plus transcriptional reporter plus in vivo functional data; single lab\",\n      \"pmids\": [\"37783676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"STAT5B acts as a transcription factor that directly drives ARRB2 transcription downstream of PRL/PRLR signaling; ARRB2 in turn physically binds ERK1/2, enhancing phosphorylation of ERK1/2 and activating the MAPK pathway to promote prostate cancer progression.\",\n      \"method\": \"ChIP-qPCR and luciferase reporter gene assay for STAT5B binding to ARRB2 promoter; Co-IP for ARRB2-ERK1/2 interaction; STAT5B and ARRB2 knockdown in VCaP and 22Rv1 cells; in vitro and in vivo tumor assays; IHC for pSTAT5B, ARRB2, pERK1/2\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, luciferase reporter, and Co-IP in single lab with in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"38341429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARRB2 deficiency (global knockout) in mice causes elevated saline intake at baseline and exacerbated fluid intake and pressor response under DOCA-salt hypertension, indicating that ARRB2 counterbalances canonical GPCR signaling to regulate fluid homeostasis and blood pressure in salt-sensitive hypertension. ARRB1 knockout did not produce the same saline intake phenotype, indicating ARRB2 specificity.\",\n      \"method\": \"Global Arrb2 knockout and Arrb1 knockout mice, 2-bottle choice paradigm, telemetric blood pressure measurement, DOCA-salt hypertension model, plasma sodium measurement\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with defined physiological phenotype and isoform-specificity control (ARRB1 KO); single lab\",\n      \"pmids\": [\"36215165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Deletion of Arrb2 in mice causes hyperactivation of Akt-mTOR signaling in the hippocampus, resulting in decreased autophagy (reduced LC3B), and mitochondrial dysfunction characterized by reduced membrane potential and ATP production and increased ROS in hippocampal neurons.\",\n      \"method\": \"Arrb2-/- mice, western blot for LC3B, Akt, mTOR and downstream targets, mitochondrial membrane potential assay, ATP measurement, ROS detection in hippocampal neurons\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with multiple molecular and cellular readouts; single lab, no rescue experiment\",\n      \"pmids\": [\"36796753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"REG3A functions as an exocytosis protein that binds to GPR54, increasing membrane localization of GPR54, which then engages ARRB2 as a scaffolding molecule to activate ERK1/2 signaling and suppress gemcitabine-induced apoptosis in pancreatic cancer cells.\",\n      \"method\": \"RNA-seq, PPI analysis, Co-IP for REG3A-GPR54 and GPR54-ARRB2 interactions, ARRB2 siRNA, GPR54 antagonist KP234, Reg3g knockout mice, in vitro and in vivo gemcitabine resistance assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP-based complex identification with genetic and pharmacological epistasis in vitro and in vivo; single lab\",\n      \"pmids\": [\"40935160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARRB2 is the direct target of miR-361, and the lncRNA GATA3-AS1 acts as a ceRNA to sequester miR-361, thereby indirectly upregulating ARRB2. ARRB2 activates the Src/Akt pathway in endometrial carcinoma cells, promoting invasion and migration.\",\n      \"method\": \"Dual-luciferase reporter assay and RNA immunoprecipitation (RIP) for miR-361/ARRB2 interaction and GATA3-AS1/miR-361 interaction; western blot for Src/Akt; ARRB2 overexpression/knockdown; in vivo xenograft assays\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — luciferase and RIP confirm miR-361 targeting of ARRB2, but the ARRB2-Src/Akt pathway link relies on single western blot readout without direct ARRB2-Src binding evidence\",\n      \"pmids\": [\"35788718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARRB2 stabilizes CDC25A mRNA through IGF2BP1 in an m6A-dependent manner; CDC25A in turn promotes FOXO3 phosphorylation and cytoplasmic retention, enabling Snail1 transcription and EMT, thereby facilitating cervical cancer proliferation and metastasis.\",\n      \"method\": \"RNA immunoprecipitation (RIP) for ARRB2-IGF2BP1-CDC25A mRNA complex, m6A methylation assay, ARRB2 and CDC25A knockdown/overexpression, western blot, in vivo tumor models\",\n      \"journal\": \"NPJ precision oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — RIP demonstrates complex formation, but mechanistic dissection of ARRB2-IGF2BP1-mRNA interaction is limited to single-lab functional readouts without reconstitution\",\n      \"pmids\": [\"40119070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"METTL3-dependent m6A methylation of ARRB2 mRNA upregulates ARRB2 protein expression in intrahepatic cholangiocarcinoma; elevated ARRB2 then promotes YAP nuclear translocation and activates the Raf-MEK-ERK signaling axis to drive ICC malignant progression and resistance to pemigatinib.\",\n      \"method\": \"m6A methylation assay, METTL3 overexpression/knockdown, ARRB2 knockdown, YAP nuclear fractionation, western blot for Raf-MEK-ERK, pemigatinib resistance assays in vitro and in vivo\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional epistasis with multiple readouts but mechanistic link between ARRB2 and YAP nuclear translocation is based on single-lab western blot/fractionation without direct binding data\",\n      \"pmids\": [\"41986296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In Treg cells, β2-AR agonist terbutaline increases ARRB2 expression and phospho-ERK1/2 levels; ARRB2 gene silencing reduces this pERK1/2 increase and impairs TGF-β and IL-10 production, while ARRB2 overexpression enhances these effects. Adoptive transfer of ARRB2-overexpressing Treg cells into CIA mice reduces joint inflammation and Th17 cytokine production, placing the β2-AR/ARRB2/ERK1/2 axis as a non-canonical signaling pathway that enhances Treg suppressive function.\",\n      \"method\": \"ARRB2 siRNA and overexpression in iTreg cells, western blot for pERK1/2, ELISA for TGF-β and IL-10, Teff proliferation suppression assay, adoptive transfer into CIA mice, clinical arthritis scoring, cytokine measurement\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with in vivo adoptive transfer rescue; single lab with multiple orthogonal readouts\",\n      \"pmids\": [\"41107955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Cryo-EM structures of mGluR8 with β-arr1 and molecular dynamics simulations reveal that β-arrestin (including β-arr2 as part of mGluR/β-arr1/β-arr2 megacomplexes identified by combinatorial mutagenesis) couples to dimeric family C GPCRs with 2:1 or 2:2 stoichiometry via 'tail' and 'core' interactions, and that β-arr-bound mGluR8 adopts a transducer-specific active state; steric interaction with both subunits and lipid bilayer supports a desensitization mechanism.\",\n      \"method\": \"Cryo-EM structural determination, single-molecule pulldown stoichiometry assay, single-molecule FRET, molecular dynamics simulations, combinatorial mutagenesis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — cryo-EM structure + MD + smFRET + mutagenesis is rigorous, but β-arr2-specific findings (megacomplex identification) are limited within a predominantly β-arr1-focused study; preprint not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In hepatocytes, Arrb2 remodels bile acid metabolism by upregulating Cyp7a1, increasing levels of the bile acid metabolite 6-ketoLCA; 6-ketoLCA in turn activates TGR5 on macrophages to promote M2 polarization, thereby attenuating hepatic ischemia-reperfusion injury. The drug dutasteride was identified as an enhancer of the Arrb2 promoter that upregulates Arrb2 expression.\",\n      \"method\": \"Hepatocyte-specific and global Arrb2 models, 70% hepatic I/R mouse model, bile acid profiling, macrophage polarization assays (M1/M2 markers), TGR5 functional experiments, dutasteride promoter activity assay\",\n      \"journal\": \"Hepatology communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional in vivo and in vitro data with metabolite identification; mechanistic links between ARRB2, Cyp7a1, and 6-ketoLCA are correlative rather than directly reconstituted; single lab\",\n      \"pmids\": [\"42043875\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARRB2 (β-arrestin 2) is a multifunctional cytoplasmic scaffolding protein that negatively regulates GPCR signaling by physically assembling multi-protein complexes at activated receptors; it suppresses NF-κB inflammatory signaling by recruiting TRAF6 and PP2A to the DRD5 receptor complex, sequesters JNK in the cytoplasm to dampen mu-opioid receptor-mediated JNK activation in a ligand-specific manner, participates in AKT/PDE4 complexes in lipid rafts to modulate cAMP levels, scaffolds ERK1/2 and AKT to promote endothelial progenitor cell angiogenic functions and prostate cancer MAPK signaling, acts as a negative regulator of the NLRP3 inflammasome (competed away by SUMOylated TRPC1), and mediates fluid homeostasis and blood pressure regulation downstream of GPCRs in salt-sensitive hypertension, while its expression is itself regulated transcriptionally by Egr1 (repressed via WDR4-DDX20) and by STAT5B, and post-transcriptionally by m6A methylation and multiple miRNAs.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARRB2 (β-arrestin 2) is a multifunctional cytoplasmic scaffolding protein that assembles multi-protein complexes downstream of activated G protein-coupled receptors to both dampen and redirect signaling [#0, #19]. Structurally, it couples to dimeric family C GPCRs through combined 'tail' and 'core' interactions, supporting receptor desensitization [#19]. As a negative regulator of inflammatory signaling, ARRB2 is recruited together with TRAF6 and PP2A to the DRD5 receptor via specific motifs, where it impairs TRAF6-mediated NF-κB activation and pro-inflammatory gene expression [#0], and it binds the NLRP3 inflammasome to suppress its activation until competed away by SUMOylated TRPC1 [#9]. ARRB2 also sequesters JNK in the cytoplasm of sensory neurons to restrain mu-opioid receptor-driven JNK signaling in a ligand-specific manner [#3], and participates in an AKT/ARRB2/PDE4 lipid-raft complex that degrades cAMP [#1]. Beyond suppression, ARRB2 directly binds and activates ERK1/2 and AKT to scaffold proliferative and pro-survival MAPK signaling across endothelial progenitor cells, prostate cancer, and GPR54/KISS1R-dependent neuroprotection [#5, #11, #8]. Physiologically, ARRB2 counterbalances GPCR signaling to control fluid homeostasis and blood pressure in salt-sensitive hypertension in an isoform-specific manner [#12], and its loss hyperactivates Akt-mTOR signaling with impaired autophagy and mitochondrial function [#13]. ARRB2 expression is itself tightly controlled, being transcriptionally driven by STAT5B and Egr1 (the latter repressed via WDR4-DDX20) [#11, #10].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing the physical genomic location of human ARRB2 anchored it as a discrete gene available for functional study.\",\n      \"evidence\": \"FISH mapping to chromosome band 17p13\",\n      \"pmids\": [\"7695743\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional or mechanistic information conveyed\", \"Does not address protein activity or partners\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Resolved how ARRB2 shapes opioid receptor outputs by showing it spatially confines JNK signaling, explaining ligand-biased behavioral phenotypes.\",\n      \"evidence\": \"β-arr2 knockout mice with JNK inhibitor epistasis and immunofluorescence in DRG neurons, plus morphine/fentanyl ligand controls\",\n      \"pmids\": [\"22491351\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARRB2-JNK binding interface not mapped\", \"Mechanism of cytoplasmic sequestration not biochemically defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified ARRB2 as a structural component of a lipid-raft cAMP-degrading machine, linking it to control of NF-κB-driven cytokine production.\",\n      \"evidence\": \"Co-IP of AKT/ARRB2/PDE4 complex, lipid raft fractionation, and miR-150 luciferase targeting assay\",\n      \"pmids\": [\"26549736\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Complex not reconstituted in vitro\", \"Stoichiometry and direct contacts within the trimer unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a receptor-templated mechanism for ARRB2's anti-inflammatory role, showing DRD5 recruits ARRB2 and PP2A to inactivate TRAF6-NF-κB signaling.\",\n      \"evidence\": \"Reciprocal Co-IP with EFD/IYX(X)I/L motif mutagenesis plus macrophage and in vivo sepsis/meningitis models\",\n      \"pmids\": [\"32035036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ARRB2 directs PP2A activity onto TRAF6 substrates not detailed\", \"Generalizability to other GPCR-TRAF6 axes untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed ARRB2 acts as a positive scaffold for ERK1/2 and AKT, broadening its role from signaling brake to pro-proliferative/pro-survival driver across cell types.\",\n      \"evidence\": \"Co-IP of ARRB2-ERK1/2 and ARRB2-AKT plus gain/loss-of-function in EPCs and KISS1R-dependent neuroprotection models in vivo\",\n      \"pmids\": [\"32863967\", \"33989759\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interfaces with ERK1/2 and AKT not mapped\", \"Context that switches ARRB2 between inhibitory and activating modes unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated an isoform-specific physiological function for ARRB2 in counterbalancing GPCR signaling for fluid and blood pressure homeostasis.\",\n      \"evidence\": \"Global Arrb2 and Arrb1 knockout mice with 2-bottle choice, telemetric BP, and DOCA-salt hypertension model\",\n      \"pmids\": [\"36215165\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific GPCRs/tissues mediating the phenotype not identified\", \"Molecular mechanism downstream of ARRB2 in this axis undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected ARRB2 levels to disease-relevant signaling rewiring, showing both that elevated ARRB2 drives pulmonary hypertension phenotypes and that ARRB2 loss deranges Akt-mTOR/autophagy in neurons.\",\n      \"evidence\": \"BMPR2 KO + ARRB2 reduction genetic epistasis in mouse/human PASMC; Arrb2-/- mice with autophagy and mitochondrial readouts in hippocampus\",\n      \"pmids\": [\"36744494\", \"36796753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARRB2 effectors in the AKT-GSK3β-β-catenin cascade not defined\", \"Neuronal phenotype lacks rescue experiment\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined transcriptional control of ARRB2, identifying an Egr1-driven program repressed by a WDR4-DDX20 adaptor module.\",\n      \"evidence\": \"Co-IP of WDR4-DDX20-Egr1, fractionation, Egr1-ARRB2 luciferase reporter in bladder cancer cells\",\n      \"pmids\": [\"37783676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct Egr1 binding site on ARRB2 promoter not finely mapped\", \"Whether this regulation operates outside bladder cancer untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked an upstream transcription factor to ARRB2's pro-tumorigenic MAPK scaffolding, showing STAT5B drives ARRB2 to potentiate ERK1/2.\",\n      \"evidence\": \"ChIP-qPCR and luciferase for STAT5B-ARRB2 promoter binding plus ARRB2-ERK1/2 Co-IP and prostate cancer in vivo assays\",\n      \"pmids\": [\"38341429\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ARRB2 enhances ERK1/2 phosphorylation mechanistically unclear\", \"Receptor input upstream of this scaffold not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Refined the structural basis for ARRB2 coupling to family C GPCRs and its competitive displacement at the inflammasome.\",\n      \"evidence\": \"Cryo-EM/smFRET/MD of mGluR-β-arrestin megacomplexes (preprint); Co-IP and domain mapping of TRPC1-ARRB2 versus NLRP3-ARRB2 in stroke models\",\n      \"pmids\": [\"39921112\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"β-arr2-specific structural detail limited within a β-arr1-focused study\", \"How SUMO-driven competition is regulated in vivo not fully resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Expanded ARRB2's reach into post-transcriptional and metabolic regulation, with m6A-dependent control of ARRB2 and ARRB2-mediated effects on lipid and bile acid metabolism and immune cell function.\",\n      \"evidence\": \"m6A assays, RIP, METTL3/IGF2BP1 manipulation, AMPK pathway readouts, metabolomics, and Treg adoptive transfer across multiple disease models\",\n      \"pmids\": [\"41986296\", \"40119070\", \"33871024\", \"41107955\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Many links (ARRB2-YAP, ARRB2-CDC25A mRNA) rest on single-lab functional readouts without reconstitution\", \"Direct biochemical contacts in these complexes not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved what determines whether ARRB2 acts as a signaling brake (NF-κB, JNK, NLRP3) versus a positive scaffold (ERK1/2, AKT) at a given receptor and cellular context.\",\n      \"evidence\": \"No single study in the corpus reconciles the inhibitory and activating modes mechanistically\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural or biochemical switch identified\", \"Receptor- and cell-type-specific partner selection rules undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 5, 11, 1, 9]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 9, 0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 11, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 9, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 5]}\n    ],\n    \"complexes\": [\n      \"AKT/ARRB2/PDE4 complex\",\n      \"DRD5-ARRB2-TRAF6-PP2A complex\",\n      \"NLRP3/ARRB2 complex\"\n    ],\n    \"partners\": [\n      \"TRAF6\",\n      \"PP2A\",\n      \"PDE4\",\n      \"AKT\",\n      \"ERK1/2\",\n      \"JNK\",\n      \"NLRP3\",\n      \"TRPC1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}